Clinical Trial Update: Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating metformin with or without a fasting-mimicking diet for Advanced LKB1-inactive Lung Adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lkb1-inactive Lung Adenocarcinoma
• Lung Adenocarcinoma

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Marina Garassino | Conditions: Advanced LKB1-inactive Lung Adenocarcinoma | Phase 2 | Status: UNKNOWN